Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus CYCLESSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus CYCLESSA.
ARANELLE vs CYCLESSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive